FY2025 EPS Estimates for Amgen Cut by Cantor Fitzgerald

Amgen Inc. (NASDAQ:AMGNFree Report) – Analysts at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for Amgen in a report issued on Thursday, October 9th. Cantor Fitzgerald analyst C. Gould now forecasts that the medical research company will earn $21.30 per share for the year, down from their previous forecast of $21.35. Cantor Fitzgerald currently has a “Neutral” rating and a $305.00 target price on the stock. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share.

Amgen (NASDAQ:AMGNGet Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.28 by $0.74. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The business had revenue of $9.18 billion for the quarter, compared to analyst estimates of $8.86 billion. During the same quarter in the prior year, the firm posted $4.97 earnings per share. The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS.

Several other equities analysts have also weighed in on AMGN. Wall Street Zen lowered Amgen from a “buy” rating to a “hold” rating in a research note on Saturday. William Blair reissued an “outperform” rating on shares of Amgen in a research note on Tuesday, June 24th. UBS Group cut their target price on Amgen from $326.00 to $317.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 6th. Bank of America increased their target price on Amgen from $261.00 to $272.00 and gave the company an “underperform” rating in a research note on Friday, September 26th. Finally, Weiss Ratings raised Amgen from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, October 8th. Eight analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Amgen presently has a consensus rating of “Hold” and a consensus price target of $309.42.

View Our Latest Stock Analysis on AMGN

Amgen Trading Up 0.5%

NASDAQ:AMGN opened at $293.85 on Monday. Amgen has a 1-year low of $253.30 and a 1-year high of $335.88. The business’s 50-day moving average price is $286.46 and its two-hundred day moving average price is $287.37. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24. The firm has a market capitalization of $158.20 billion, a price-to-earnings ratio of 24.03, a PEG ratio of 2.54 and a beta of 0.49.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Friday, September 12th. Stockholders of record on Friday, August 22nd were given a dividend of $2.38 per share. The ex-dividend date of this dividend was Friday, August 22nd. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.2%. Amgen’s dividend payout ratio (DPR) is currently 77.84%.

Insider Activity at Amgen

In other news, SVP Nancy A. Grygiel sold 1,267 shares of the firm’s stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total transaction of $376,286.33. Following the sale, the senior vice president owned 7,209 shares of the company’s stock, valued at $2,141,000.91. This trade represents a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.69% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Amgen

A number of hedge funds have recently modified their holdings of the business. Brighton Jones LLC grew its holdings in shares of Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after buying an additional 5,226 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Amgen by 40.2% during the first quarter. GAMMA Investing LLC now owns 11,753 shares of the medical research company’s stock worth $3,662,000 after buying an additional 3,369 shares in the last quarter. Goldstone Financial Group LLC bought a new position in shares of Amgen during the first quarter worth about $239,000. Griffin Asset Management Inc. bought a new position in shares of Amgen during the first quarter worth about $230,000. Finally, Tritonpoint Wealth LLC grew its holdings in shares of Amgen by 5.7% during the first quarter. Tritonpoint Wealth LLC now owns 1,828 shares of the medical research company’s stock worth $569,000 after buying an additional 99 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

About Amgen

(Get Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Further Reading

Earnings History and Estimates for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.